Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Javier Vázquez Correa
 + 1508 word(s) 1508 2022-02-16 09:53:36 |
2 format correct
Catherine Yang
 Meta information modification 1508 2022-02-17 04:00:38 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Vázquez Correa, J. Attention Deficit Hyperactivity Disorder (ADHD). Encyclopedia. Available online: https://encyclopedia.pub/entry/19551 (accessed on 09 August 2024).
Vázquez Correa J. Attention Deficit Hyperactivity Disorder (ADHD). Encyclopedia. Available at: https://encyclopedia.pub/entry/19551. Accessed August 09, 2024.
Vázquez Correa, Javier. "Attention Deficit Hyperactivity Disorder (ADHD)" Encyclopedia, https://encyclopedia.pub/entry/19551 (accessed August 09, 2024).
Vázquez Correa, J. (2022, February 17). Attention Deficit Hyperactivity Disorder (ADHD). In Encyclopedia. https://encyclopedia.pub/entry/19551
Vázquez Correa, Javier. "Attention Deficit Hyperactivity Disorder (ADHD)." Encyclopedia. Web. 17 February, 2022.
Attention Deficit Hyperactivity Disorder (ADHD)
Edit
This entry is adapted from the peer-reviewed paper 10.3390/nu14040739

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by a persistent pattern of inattention and/or hyperactivity-impulsivity. ADHD impairments arise from irregularities primarily in dopamine (DA) and norepinephrine (NE) circuits within the prefrontal cortex.

attention deficit hyperactivity disorder impulsivity ADHD

1. Introduction

Attention Deficit Hyperactivity Disorder (ADHD) is the most commonly diagnosed and treated mental disorder during childhood [1] and it is increasingly diagnosed and treated in during adulthood [2]. ADHD is a neurodevelopmental disorder characterized by a pattern of inattention and/or hyperactivity-impulsivity, persisting no less than six months, that is inconsistent with developmental level and has negative impact in at least two settings (academic, occupational or social) [3]. Inattention refers to important difficulties in sustaining attention to tasks that do not deliver a high level of stimulation or regular rewards, distractibility, and difficulties with organisation. Hyperactivity refers to disproportionate motor activity and difficulties with remaining still, most manifest in structured situations that involve behavioral self-control. Finally, impulsivity is a propensity to behave in response to immediate stimuli, without consideration of the risks and consequences [4]. Specific manifestations vary across individuals, and may change over the course of development. Depending on the symptoms presented, three different types of ADHD can be diagnosed: predominantly inattentive presentation, predominantly hyperactive-impulsive presentation, or combined presentation [3][4]. Although ADHD onset occurs during childhood and it often persists into adulthood, there is an important knowledge gap concerning ADHD lifespan aspects [5]. Population surveys suggest that ADHD occurs in most cultures in about 5% of children and about 2.5% of adults [6] and, as of 2019, it was estimated to affect 84.7 million people worldwide [7]. ADHD management recommendations depend on the country [8][9][10] and usually include psychotherapy (essentially Cognitive Behavior Therapy, CBT), lifestyle changes and medications [11]. ADHD medication treatment, however, has been historically considered controversial [12], particularly due to its side effects [13][14][15]. In the face of these controversies and high rates of diagnosis, alternative/complementary pharmacological therapeutic approaches for ADHD are needed.
Although larger ADHD models containing supplementary pathways have been suggested [16][17], it is widely accepted that ADHD impairments, including selective and sustained attention, impulsivity, and motor activity, arise from abnormalities in different circuits involving the prefrontal cortex [18]: sustained attention is modulated by a cortico-striato-thalamocortical (CSTC) loop that comprises the dorsolateral prefrontal cortex (DLPFC) projecting to the striatal complex. Selective attention is modulated by a cortico-striato-thalamo-cortical (CSTC) loop ascending from the dorsal anterior cingulate cortex (dACC) and projecting to the striatal complex, followed by the thalamus, and back to the dACC. Impulsivity is related to a cortico-striato-thalamocortical (CSTC) loop that contains the orbitofrontal cortex (OFC), the striatal complex, and the thalamus. Finally, motor activity, including hyperactivity and psychomotor agitation or retardation, can be modulated by a cortico-striato-thalamo-cortical (CSTC) loop arising from the prefrontal motor cortex to the lateral striatum to the thalamus and back to the prefrontal motor cortex. ADHD patients cannot activate prefrontal cortex areas in an appropriate manner when responding to cognitive tasks requiring attention and executive control, and show a dysfunction in reward and motivation, hindering cognitive control of behaviour [19][20]. Children diagnosed with ADHD, in this regard, need stronger incentives to adapt their behaviour [21], showing impaired responses to partial schedules of reinforcement and difficulties in delaying gratification [22][23].
In ADHD, inefficient information processing and arousal-related behaviours are hypothetically caused by imbalances mainly in the dopamine (DA) and norepinephrine (NE) circuits [24][25] and the serotonin (5-HT), glutamate (GLU), and acetylcholine (ACh) pathways within these areas of the brain [26][27][28].

2. Researches and Findings

ADHD is characterized by symptoms including attention deficits, impulsivity, and hyperactivity [3][4] that frequently persist throughout life [1][2][6]. Prefrontal cortex function modulation and attentional/behavioral regulation depends on the optimal release of signalling molecules such as NE, DA [24][25], as well as 5-HT, GLU, or ACh [26][27][28]. In this respect, genes, including the DAT or the DRD4 [29][30] or the SERT, the SNAP-25, and the BDNF [31][32], might play a role in causing ADHD. Therefore, agents that can lead to the optimal balance of these organic compounds are hypothetically beneficial in patients with ADHD by mainly returning prefrontal activity to adequate functional levels [18][33]. In this sense, it has long been discussed whether caffeine could become an effective pharmacological compound for the management of symptoms of ADHD [34][35].
Regarding attention, caffeine treatment improved the attentional and behavioral flexibility of SHRs [36], the spatial attention of 6-OHDA lesioned rats [37], and SI in ICR mice [38] during adolescence. Caffeine treatment improved the reaction time of LE and CD rats [39] and focus and attention in zebrafish [40] during adulthood.
Regarding learning and memory, caffeine treatment plus physical exercise during adulthood and adolescence improved working memory in SHRs [41]. In the same vein, caffeine treatment alone restored non-associative learning in female SHRs [42], improved working memory in SHRs [43], female SHRs [44], and adolescent SHRs [42]. The administration of caffeine improved spatial learning deficit in SHRs, increased memory retention in WKY rats [45], and improved spatial short-term memory in SHRs [36] and female SHRs [42].
Concerning olfactory discrimination, caffeine treatment, together with physical exercise, was able to restore olfactory discrimination in SHRs during adolescence or adulthood [41]. Concerning blood pressure, caffeine treatment did not alter the hypertensive phenotype in SHR [45][44] during adolescence or adult life [41], nor during the adult female SHR prepubertal period [43]. Finally, caffeine treatment did not alter body weight in SHRs [36][43].
Beyond its clear effects on improving performance in tasks requiring attention, learning, memory and olfactory discrimination, without altering blood pressure and body weight, the implication of caffeine in modulating ADHD-like hyperactivity symptoms remains controversial. Indeed, caffeine treatment plus physical exercise did not affect locomotor activity in SHRs [41]. In a similar manner, caffeine treatment alone did not alter locomotion in SHR [36][43][45], preadolescent SHR [42], or young LDLr mice [46]. Nonetheless, caffeine treatment did increase locomotor activity in adolescent female SHRs [42], zebrafish [40]. Furthermore, it produced an increase related to dose in locomotion in CD rats and a significant attenuation of CGS-21680-induced hypolocomotion in CD rats [39], and it attenuated locomotor activity in middle-aged LDLr mice [46] and 6-OHDA lesioned rats throughout the prepubertal period [37]. This apparent discrepancy may have resulted from caffeine ‘s promotion of different effects according to age and sex. In this regard, Nunes et al. [42] suggested that the intake of caffeine from the childhood period onwards may aggravate hyperactivity in females, if the consumption continues up to the adolescence period. Szczepanik et al. [46] linked the age-dependent effect induced by caffeine with the idea that the blockade of adenosine A1/A2A receptors attempts to renormalize a potentially maladaptive system [47], with age an important escalating factor in mice. In a different study, Ruiz-Oliveira et al. [40] proposed that caffeine-induced bursts of locomotion may be caused by a decrease in fatigue [48] rather than by an anxiogenic response. Importantly, the attenuation of motor activity by caffeine consumption was determined as a natural effect of growth rather than an effect of caffeine intake by Caballero et al. [37].
In terms of impulsivity, although acute pretreatment with caffeine increased the number of large-reward choices made by SHRs, chronic treatment with caffeine increased the impulsive phenotype and decreased choices of large rewards by SHRs [49]. This discrepancy may be explained by previous studies performed on animal models of brain diseases, showing that while acute treatment acts mainly on A1 receptors, chronic treatment acts mainly on A2A receptors [50]. Leffa et al. [49], in this direction, underscored the ability of the adenosine modulation system to control behavioral inhibition.
Besides reviewing animal studies deciphering the effects of caffeine in the modulation of ADHD-like symptoms, we reviewed for the first time animal studies examining the effects of caffeine and adenosine receptors on neurons isolated from SHRs, at the neuronal level.
In this respect, treatment with caffeine and physical exercise during the adolescence period augmented the quantity of SNAP-25, syntaxin, and serotonin in the prefrontal cortex and the hippocampus, as well as striatal dopamine quantity, in SHRs [41]. In a similar manner, caffeine treatment alone during the adolescence period attenuated the improvement in DAT density in the fronto-cortical and striatal terminals of SHRs and diminished the dopamine uptake by synaptosomes from SHRs’ fronto-cortical and striatal terminals [36]. Furthermore, Pandolfo et al. [36] demonstrated that fronto-cortical nerve terminals are provided with AdenosineA2A receptor, the target of chronic caffeine exposure, whose density was found to be increased in SHRs. Caffeine treatment normalized BDNF levels in the hippocampuses of SHR males, while the same treatment normalized TrkB receptors TrkB-FL and TrkB-T SHR in the hippocampuses of SHR females [42]. Finally, neurons from SHRs showed an inferior number of zero-branch points, and a superior number of two-branch-points-neurons following in vitro caffeine treatment consisting of 24 h of caffeine incubation. After treatment with caffeine, an increase in the total and maximal neurite length and a tendency toward a superior number of one-branch-point neurons was also observed for SHR neurons. The effect of caffeine on increasing maximal neurite length, and on recuperating the entire neurite length of neurons from SHR, was entirely blocked by PKA inhibitor. LY294002, as an inhibitor of PI3K, blocked caffeine’s effects on the increase in the amount of branch points in SHR neurons. Finally, the effect of caffeine on the prevention of reductions in the total neurite length, increasing maximal neurite length, and the number of roots was eradicated by the presence of PI3K inhibitor in SHR neurons [51].

References

  1. Ferguson, J.H. National Institutes of Health Consensus Development Conference Statement: Diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD). J. Am. Acad. Child Adolesc. Psychiatry 2000, 39, 182–193.
  2. Dopheide, J.A.; Pliszka, S.R. Attention-deficit-hyperactivity disorder: An update. Pharmacotherapy 2009, 29, 656–679.
  3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5; American Psychiatric Association: Arlington, VA, USA, 2013.
  4. ICD-11: 6A05 Attention Deficit Hyperactivity Disorder. Available online: https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f821852937 (accessed on 22 December 2021).
  5. Franke, B.; Michelini, G.; Asherson, P.; Banaschewski, T.; Bilbow, A.; Buitelaar, J.K.; Cormand, B.; Faraone, S.V.; Ginsberg, Y.; Haavik, J.; et al. Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. Eur. Neuropsychopharmacol. 2018, 28, 1059–1088.
  6. Tsuang, M.T.; Tohen, M.; Jones, P. Textbook of Psychiatric Epidemiology, 3rd ed.; John Wiley & Sons: Chichester, UK, 2011.
  7. Global Health Metrics: Attention-Deficit/Hyperactivity Disorder—Level 3 Cause. Available online: https://www.thelancet.com/pb-assets/Lancet/gbd/summaries/diseases/adhd.pdf (accessed on 22 December 2021).
  8. NICE Guideline —Attention Deficit Hyperactivity Disorder: Diagnosis and Management. Available online: https://www.nice.org.uk/guidance/ng87/ (accessed on 22 December 2021).
  9. Canadian ADHD Practice Guidelines. Available online: https://www.caddra.ca/cms4/pdfs/caddraGuidelines2011Introduction.pdf (accessed on 22 December 2021).
  10. Centers for Disease Control and Prevention: ADHD Treatment Recommendations. Available online: https://www.cdc.gov/ncbddd/adhd/guidelines.html (accessed on 22 December 2021).
  11. Wolraich, M.L.; Hagan, J.F.; Allan, C.; Chan, E.; Davison, D.; Earls, M.; Evans, S.W.; Flinn, S.K.; Froehlich, T.; Frost, J.; et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2019, 144, e20192528.
  12. Schonwald, A.; Lechner, E. Attention deficit/hyperactivity disorder: Complexities and controversies. Curr. Opin. Pediatr. 2006, 18, 189–195.
  13. Wigal, S.B. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 2009, 23, 21–31.
  14. Parker, J.; Wales, G.; Chalhoub, N.; Harpin, V. The long-term outcomes of interventions for the management of attention-deficit hyperactivity disorder in children and adolescents: A systematic review of randomized controlled trials. Psychol. Res. Behav. Manag. 2013, 6, 87.
  15. Arnold, L.E.; Hodgkins, P.; Caci, H.; Kahle, J.; Young, S. Effect of treatment modality on long-term outcomes in attention-deficit/hyperactivity disorder: A systematic review. PLoS ONE 2015, 10, e0116407.
  16. Castellanos, F.X.; Proal, E. Large-scale brain systems in ADHD: Beyond the prefrontal–striatal model. Trends Cogn. Sci. 2012, 16, 17–26.
  17. Cortese, S.; Kelly, C.; Chabernaud, C.; Proal, E.; Di Martino, A.; Milham, M.P.; Castellanos, F.X. Toward systems neuroscience of ADHD: A meta-analysis of 55 fMRI studies. Am. J. Psychiatry 2012, 169, 1038–1055.
  18. Stahl, S.M. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 4th ed.; Cambridge University Press: Cambridge, UK, 2013.
  19. Haenlein, M.; Caul, W.F. Attention deficit disorder with hyperactivity: A specific hypothesis of reward dysfunction. J. Am. Acad. Child Adolesc. Psychiatry 1987, 26, 356–362.
  20. Johansen, E.B.; Killeen, P.R.; Russell, V.A.; Tripp, G.; Wickens, J.R.; Tannock, R. Origins of altered reinforcement effects in ADHD. Behav. Brain Funct. 2009, 5, 7.
  21. Kollins, S.H.; Lane, S.D.; Shapiro, S.K. The experimental analysis of childhood psychopathology: A matching analysis of the behavior of children diagnosed with Attention Deficit Hyperactivity Disorder. Psychol. Record. 1997, 47, 25–44.
  22. Sonuga-Barke, E.J. The dual pathway model of AD/HD: An elaboration of neuro-developmental characteristics. Neurosci. Biobehav. Rev. 2003, 27, 593–604.
  23. Tripp, G.; Wickens, J.R. Research review: Dopamine transfer deficit: A neurobiological theory of altered reinforcement mechanisms in ADHD. J. Child Psychol. Psychiatry 2008, 49, 691–704.
  24. Nestler, E.J.; Hyman, S.E.; Malenka, R.C.; Holtzman, D.M. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience, 2nd ed.; McGraw-Hill Medical: New York, NY, USA, 2009.
  25. Biederman, J.; Faraone, S.V. Current concepts on the neurobiology of Attention-Deficit/Hyperactivity Disorder. J. Atten. Disord. 2002, 6, 7–16.
  26. Bidwell, L.C.; McClernon, F.J.; Kollins, S.H. Cognitive enhancers for the treatment of ADHD. Pharmacol. Biochem. Behav. 2011, 99, 262–274.
  27. Cortese, S. The neurobiology and genetics of attention-deficit/hyperactivity disorder (ADHD): What every clinician should know. Eur. J. Paediatr. Neurol. 2012, 16, 422–433.
  28. Lesch, K.P.; Merker, S.; Reif, A.; Novak, M. Dances with black widow spiders: Dysregulation of glutamate signalling enters centre stage in ADHD. Eur. Neuropsychopharmacol. 2013, 23, 479–491.
  29. Berry, M.D. The potential of trace amines and their receptors for treating neurological and psychiatric diseases. Rev. Recent Clin. Trials. 2007, 2, 3–19.
  30. Sotnikova, T.D.; Caron, M.G.; Gainetdinov, R.R. Trace amine-associated receptors as emerging therapeutic targets. Mol. Pharmacol. 2009, 76, 229–235.
  31. Gizer, I.R.; Ficks, C.; Waldman, I.D. Candidate gene studies of ADHD: A meta-analytic review. Hum. Genet. 2009, 126, 51–90.
  32. Kebir, O.; Joober, R. Neuropsychological endophenotypes in attention-deficit/hyperactivity disorder: A review of genetic association studies. Eur. Arch. Psychiatry Clin. Neurosci. 2011, 261, 583–594.
  33. Chandler, D.J.; Waterhouse, B.D.; Gao, W.J. New perspectives on catecholaminergic regulation of executive circuits: Evidence for independent modulation of prefrontal functions by midbrain dopaminergic and noradrenergic neurons. Front. Neural Circuits 2014, 8, 53.
  34. Leon, M.R. Effects of caffeine on cognitive, psychomotor, and affective performance of children with attention-deficit/hyperactivity disorder. J. Atten. Disord. 2000, 4, 27–47.
  35. Ioannidis, K.; Chamberlain, S.R.; Müller, U. Ostracising caffeine from the pharmacological arsenal for attention-deficit hyperactivity disorder—Was this a correct decision? A literature review. J. Psychopharmacol. 2014, 28, 830–836.
  36. Pandolfo, P.; Machado, N.J.; Köfalvi, A.; Takahashi, R.N.; Cunha, R.A. Caffeine regulates frontocorticostriatal dopamine transporter density and improves attention and cognitive deficits in an animal model of attention deficit hyperactivity disorder. Eur. Neuropsychopharmacol. 2013, 23, 317–328.
  37. Caballero, M.; Núñez, F.; Ahern, S.; Cuffí, M.L.; Carbonell, L.; Sánchez, S.; Fernández-Dueñas, V.; Ciruela, F. Caffeine improves attention deficit in neonatal 6-OHDA lesioned rats, an animal model of attention deficit hyperactivity disorder (ADHD). Neurosci. Lett. 2011, 494, 44–48.
  38. Ouchi, H.; Ono, K.; Murakami, Y.; Matsumoto, K. Social isolation induces deficit of latent learning performance in mice: A putative animal model of attention deficit/hyperactivity disorder. Behav. Brain. Res. 2013, 238, 146–153.
  39. Higgins, G.A.; Grzelak, M.E.; Pond, A.J.; Cohen-Williams, M.E.; Hodgson, R.A.; Varty, G.B. The effect of caffeine to increase reaction time in the rat during a test of attention is mediated through antagonism of adenosine A2A receptors. Behav. Brain. Res. 2007, 185, 32–42.
  40. Ruiz-Oliveira, J.; Silva, P.F.; Luchiari, A.C. Coffee time: Low caffeine dose promotes attention and focus in zebrafish. Learn. Behav. 2019, 47, 227–233.
  41. França, A.P.; Schamne, M.G.; de Souza, B.S.; da Luz Scheffer, D.; Bernardelli, A.K.; Corrêa, T.; de Souza Izídio, G.; Latini, A.; da Silva-Santos, J.E.; Canas, P.M.; et al. Caffeine consumption plus physical exercise improves behavioral impairments and stimulates neuroplasticity in Spontaneously Hypertensive Rats (SHR): An animal model of attention deficit hyperactivity disorder. Mol. Neurobiol. 2020, 57, 3902–3919.
  42. Nunes, F.; Pochmann, D.; Almeida, A.S.; Marques, D.M.; Porciúncula, L.O. Differential behavioral and biochemical responses to caffeine in male and female rats from a validated model of attention deficit and hyperactivity disorder. Mol. Neurobiol. 2018, 55, 8486–8498.
  43. Pires, V.A.; Pamplona, F.A.; Pandolfo, P.; Prediger, R.D.S.; Takahashi, R.N. Chronic caffeine treatment during prepubertal period confers long-term cognitive benefits in adult spontaneously hypertensive rats (SHR), an animal model of attention deficit hyperactivity disorder (ADHD). Behav. Brain. Res. 2010, 215, 39–44.
  44. Pires, V.A.; Pamplona, F.A.; Pandolfo, P.; Fernandes, D.; Prediger, R.D.; Takahashi, R.N. Adenosine receptor antagonists improve short-term object-recognition ability of spontaneously hypertensive rats: A rodent model of attention-deficit hyperactivity disorder. Behav. Pharmacol. 2009, 20, 134–145.
  45. Prediger, R.D.S.; Pamplona, F.A.; Fernandes, D.; Takahashi, R.N. Caffeine improves spatial learning deficits in an animal model of attention deficit hyperactivity disorder (ADHD)-the spontaneously hypertensive rat (SHR). Int. J. Neuropsychopharmacol. 2005, 8, 583–594.
  46. Szczepanik, J.C.; de Oliveira, P.A.; de Oliveira, J.; Mack, J.M.; Engel, D.F.; Rial, D.; Moreira, E.L.; de Bem, A.F.; Prediger, R.D. Caffeine Mitigates the Locomotor Hyperactivity in Middle-aged Low-density Lipoprotein Receptor (LDLr)-Knockout Mice. CNS Neurosci. Ther. 2016, 22, 420.
  47. Fredholm, B.B. Adenosine and neuroprotection. Int. Rev. Neurobiol. 1996, 40, 259–280.
  48. Claghorn, G.C.; Thompson, Z.; Wi, K.; Van, L.; Garland, T., Jr. Caffeine stimulates voluntary wheel running in mice without increasing aerobic capacity. Physiol. Behav. 2017, 170, 133–140.
  49. Leffa, D.T.; Ferreira, S.G.; Machado, N.J.; Souza, C.M.; Rosa, F.D.; de Carvalho, C.; Kincheski, G.C.; Takahashi, R.N.; Porciúncula, L.O.; Souza, D.O. Caffeine and cannabinoid receptors modulate impulsive behavior in an animal model of attentional deficit and hyperactivity disorder. Eur. J. Neurosci. 2019, 49, 1673–1683.
  50. Cunha, R.A.; Agostinho, P.M. Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. J. Alzheimers Dis. 2010, 20, 95–116.
  51. Alves, C.B.; Almeida, A.S.; Marques, D.M.; Faé, A.H.L.; Machado, A.C.L.; Oliveira, D.L.; Porciúncula, L.O. Caffeine and adenosine A2A receptors rescue neuronal development in vitro of frontal cortical neurons in a rat model of attention deficit and hyperactivity disorder. Neuropharmacology 2020, 166, 107782.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Neurosciences
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Javier Vázquez Correa
View Times: 788
Revisions: 2 times (View History)
Update Date: 17 Feb 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback